Related Experiment Video
Updated: Jul 4, 2025

Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Ononin promotes radiosensitivity in lung cancer by inhibiting HIF-1α/VEGF pathway
Yi-Ming Zhang1, Zhi-Ming Miao1, Ya-Ping Chen1
1Provincial-Level Key Laboratory for Molecular Medicine of Major Diseases and the Prevention and Treatment with Traditional Chinese, Medicine Research in Gansu Colleges and Universities, Gansu University of Chinese Medicine, Lanzhou, PR China.
Background:
In our previous study, we provided evidence that Astragalus mongholicus Bunge(AM) and its extracts possess a protective capability against radiation-induced damage, potentially mediated through the reduction of reactive oxygen species (ROS) and nitric oxide (NO). However, we were pleasantly surprised to discover during our experimentation that AM not only offers protection against radiation damage but also exhibits a radiation sensitization effect. This effect may be attributed to a specific small molecule present in AM known as ononin. Currently, radiation sensitizers are predominantly found in nitrazole drugs and nanomaterials, with no existing reports on the radiation sensitization properties of ononin, nor its underlying mechanism.
Purpose:
This study aims to investigate the sensitization effect of the small molecule ononin derived from AM on lung cancer radiotherapy, elucidating its specific molecular mechanism of action. Additionally, the safety profile of combining astragalus small molecule ononin with radiation therapy will be evaluated.
Methods:
The effective concentration of ononin was determined through cell survival experiments, and the impact of ononin combined with varying doses of radiation on lung cancer cells was observed using CCK-8 and cell cloning experiments. The apoptotic effect of ononin combined with radiation on lung cancer cells was assessed using Hochester staining, flow cytometry, and WB assay. Additionally, WB and immunofluorescence analysis were conducted to investigate the influence of ononin on HIF-1α/VEGF pathway. Furthermore, Molecular Dynamics Simulation was employed to validate the targeted binding ability of ononin and HIF-1α. A lung cancer cell line was established to investigate the effects of knockdown and overexpression of HIF-1α. Subsequently, the experiment was repeated using tumor bearing nude mice and C57BL/6 mouse models in an in vivo study. Tumor volume was measured using a vernier caliper, while HE, immunohistochemistry, and immunofluorescence techniques were employed to observe the effects of ononin combined with radiation on tumor morphology, proliferation, and apoptosis. Additionally, Immunofluorescence was employed to examine the impact of ononin on HIF-1α/VEGF pathway in vivo, and its effect on liver function in mice was assessed through biochemistry analysis.
Results:
At a concentration of 25 μM, ononin did not affect the proliferation of lung epithelial cells but inhibited the survival of lung cancer cells. In vitro experiments demonstrated that the combination of ononin and radiation could effectively inhibit the growth of lung cancer cells, induce apoptosis, and suppress the excessive activation of the Hypoxia inducible factor 1 alpha/Vascular endothelial growth factor pathway. In vivo experiments showed that the combination of ononin and radiation reduced the size and proliferation of lung cancer tumors, promoted cancer cell apoptosis, mitigated abnormal activation of the Hypoxia inducible factor 1 alpha pathway, and protected against liver function damage.
Conclusion:
This study provides evidence that the combination of AM and its small molecule ononin can enhance the sensitivity of lung cancer to radiation. Additionally, it has been observed that this combination can specifically target HIF-1α and exert its effects. Notably, ononin exhibits the unique ability to protect liver function from damage while simultaneously enhancing the tumor-killing effects of radiation, thereby demonstrating a synergistic and detoxifying role in tumor radiotherapy. These findings contribute to the establishment of a solid basis for the development of novel radiation sensitizers derived from traditional Chinese medicine.
Insights
Astragalus mongholicus Bunge (AM) extract
Area of Science:
- Oncology
- Pharmacology
- Radiotherapy
Background:
- Astragalus mongholicus Bunge (AM) extracts show protective effects against radiation damage.
- AM exhibits a novel radiation sensitization effect attributed to the small molecule ononin.
- Ononin's radiation sensitization properties and mechanism are previously unreported.
Purpose of the Study:
- Investigate ononin's sensitization effect on lung cancer radiotherapy.
- Elucidate ononin's molecular mechanism of action.
- Evaluate the safety of combining ononin with radiation therapy.
Main Methods:
- Determined effective ononin concentration via cell survival assays.
- Assessed ononin and radiation impact on lung cancer cells (CCK-8, cloning, Hochester staining, flow cytometry, WB).
- Investigated ononin's effect on the HIF-1α/VEGF pathway (WB, immunofluorescence, molecular dynamics simulation, knockdown/overexpression studies).
- Conducted in vivo studies using tumor-bearing mice and C57BL/6 models.
- Evaluated tumor growth, apoptosis, liver function, and pathway modulation in vivo.
Main Results:
- Ononin (25 μM) inhibited lung cancer cell survival without affecting normal cells.
- Combined ononin and radiation inhibited lung cancer cell growth, induced apoptosis, and suppressed HIF-1α/VEGF pathway activation.
- In vivo studies showed reduced tumor size and proliferation, increased apoptosis, and mitigated HIF-1α pathway activation.
- Ononin combination protected against liver function damage in mice.
Conclusions:
- Ononin from AM enhances lung cancer sensitivity to radiation by targeting HIF-1α.
- Ononin demonstrates synergistic tumor-killing and protective effects on liver function.
- These findings support developing traditional Chinese medicine-derived radiation sensitizers.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy

